drugset
drugset / Trial / NCT05812430

Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer

NCT05812430 ↗

Phase 2 Unknown 20 enrolled The First Affiliated Hospital of Zhengzhou University
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of anlotinib plus TQB2450 combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer

Timeline

Start
2023-04-10
Primary completion
2023-10-10
Completion
2024-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Benmelstobart Monoclonal antibody 1200 mg Intravenous
Subject Catequentinib Small molecule 10 mg Oral
Subject Cisplatin Other / unclassified 60 mg/m2 Intravenous
Subject Paclitaxel Small molecule 200 mg/m2 Intravenous

Indications

biliary tract cancer